CG Oncology & Bristol Myers Squibb Trial Bladder Cancer Combo
Ticker: CGON · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1991792
| Field | Detail |
|---|---|
| Company | Cg Oncology, Inc. (CGON) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, clinical-trial, oncology, bladder-cancer
Related Tickers: BMY
TL;DR
CG Oncology and BMS teaming up to test cretostim + Opdualag for bladder cancer. Big potential if it works!
AI Summary
CG Oncology, Inc. announced on April 26, 2025, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will evaluate the combination of CG Oncology's lead asset, cretostim, with Bristol Myers Squibb's Opdualag (nivolumab and relatlimab-rmbw) in patients with advanced bladder cancer. The trial aims to assess the safety and efficacy of this combination therapy.
Why It Matters
This collaboration could lead to a new combination therapy for advanced bladder cancer, potentially improving treatment options for patients and expanding the market for both companies' drugs.
Risk Assessment
Risk Level: medium — The success of this trial is uncertain, and the combination therapy may not prove effective or safe, impacting CG Oncology's stock and future prospects.
Key Players & Entities
- CG Oncology, Inc. (company) — Registrant
- Bristol Myers Squibb (company) — Collaboration Partner
- cretostim (drug) — CG Oncology's lead asset
- Opdualag (drug) — Bristol Myers Squibb's drug
- nivolumab (drug) — Component of Opdualag
- relatlimab-rmbw (drug) — Component of Opdualag
- April 26, 2025 (date) — Date of earliest event reported
FAQ
What is the primary goal of the clinical trial collaboration between CG Oncology and Bristol Myers Squibb?
The primary goal is to evaluate the safety and efficacy of combining CG Oncology's cretostim with Bristol Myers Squibb's Opdualag in patients with advanced bladder cancer.
What specific drugs are involved in this collaboration?
The collaboration involves CG Oncology's cretostim and Bristol Myers Squibb's Opdualag, which is a combination of nivolumab and relatlimab-rmbw.
What type of cancer is the trial focused on?
The trial is focused on patients with advanced bladder cancer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on April 26, 2025.
What is the reported business address for CG Oncology, Inc.?
The principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, California, 92618.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding CG Oncology, Inc. (CGON).